Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission

Modern Rheumatology

Volumn 18, Issue 5, 2008, Pages 460-464

  Nawata, Masao ^a   Saito, Kazuyoshi ^a   Nakayamada, Shingo ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Discontinuation; Infliximab; Remission; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; STROMELYSIN;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE DURATION; DRUG DOSE REDUCTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; STEINBROCKER CLASSIFICATION STAGE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; YOUNG ADULT;

EID: 53549130270     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-008-0089-1     Document Type: Article

References (16)

1. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;350:2167-79.
2. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004;350:2591-602.
3. Steinman L. Immune therapy for autoimmune diseases. Science. 2004;305:212-6.
4. Firestein GS. The T cell cometh: Interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J Clin Invest. 2004;114:471-4.
5. Maini R, St Clair EW, Breedveld F, Furst D, Kalded J, Weisman, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
6. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50:1051-65.
7. Breedveld FC, Han C, Bala M, van der Heijde D, Baker D, Kavanaugh AF, et al. Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64:52-5.
8. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: Randomized, controlled trial. Arthritis Rheum. 2004;50:3432-43.
9. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patients Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomized controlled trial. Lancet. 2004;363:675-81.
10. van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: The TEMPO trial. Ann Rheum Dis. 2006;65:328-34.
11. van der Heijde D, Klareskog L, Rondriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063-74.
12. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum. 2005;52:3381-90.
13. van der Heijde DM, van Riel P, Nuver-Zwat IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;1:1036-38.
14. van der Heijde DM. Plain X-rays in rheumatoid arthritis: Overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol. 1996;10:435-53.
15. van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof MA, Van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year prospective follow-up of patients with early rheumatoid arthritis. Arthritis Rheum. 1992;35:26-34.
16. van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol. 1995;22:1792-96.